US Pharma MarketingInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.
Source: FierceBiotech